EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

MVABEA

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
R/0023	Renewal of the marketing authorisation	30/01/2025	28/03/2025	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Mvabea in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

II/0021	Update of sections 4.6 and 5.1 of the SmPC in order to update information on pregnancy based on final results from study VAC52150EBL3010 listed as a category 3 study in the RMP as well as study VAC52150EBL3008 and two post-authorisation vaccination campaigns. Study VAC52150EBL3010 is a phase 3 open-label randomized clinical trial to evaluate the safety, reactogenicity and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy pregnant women. The Package Leaflet is updated accordingly. The RMP version 4.1 has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the Product Information and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	27/02/2025		SmPC, Annex II and PL	SmPC new text Section 4.6 Pregnancy In Study EBL3010, a Phase III open label, randomised, controlled study in healthy pregnant women, the percentage of women with any adverse maternal/foetal or neonatal/infant outcome was similar in 977 (51 in the first trimester) vaccinated pregnant women versus 1 000 (51 in the first trimester) unvaccinated pregnant women (0.4% versus 0.5% for miscarriage, 0.9% versus 1.1% for congenital anomalies, 2.7% versus 3.1% for preterm birth, and 4.7% versus 5.0% for low birth weight). Twenty-two infant deaths were reported throughout the entire study: 12/964 (1.2%) infants born to vaccinated pregnant women versus 10/981 (1.0%) born to unvaccinated pregnant women. Amongst these, there was a numerical imbalance in cases of neonatal death (1.1% versus 0.5%), including neonatal deaths related to hypoxic ischaemic encephalopathy. These rates are below the background neonatal death rate of 20 per 1000 live births. Immunogenicity data was also obtained in this study. Data from 492 additional pregnancy outcomes (134 in the first trimester) from an open label Phase III study (EBL3008) and vaccination campaigns (EBL4002) and (EBL4004) revealed no vaccine associated congenital anomalies or foetal/neonatal toxicity. […] It is preferred to only use Mvabea during pregnancy if the benefits of immediate vaccination outweigh the potential risks. Section 5.1 Immunogenicity data in pregnant and postpartum women

					and infants The immune response to the 2 dose primary vaccination regimen given in an 8 week interval was assessed in pregnant women and a subset of their infants in study EBL3010. The control group received the vaccine 6 10 weeks postpartum in the same study. In this study, 99.4% of study participants mounted a binding antibody response to EBOV GP, 21 days post dose 2. At 21 days post dose 2, the GMC was numerically lower in pregnant women than in the control group. At 365 days post dose 1 (i.e. 1 year post dose 1), the difference between pregnant women and postpartum women was no longer present. For pregnant women, 99.3% (145/146) of women had a positive sample with a GMC of 2186 EU/mL at postpartum Day 1 (cord blood). In infants born to women vaccinated during pregnancy, 94.7% (71/75) had a positive sample with a GMC of 264 EU/mL at postpartum Day 99 (i.e. 14 weeks of age). For more information, please refer to the Summary of Product Characteristics.
S/0022	Annual re-assessment.	17/10/2024	n/a		
PSUSA/10857 /202309	Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN-Filo [recombinant])	25/04/2024	25/04/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10857/202309.
S/0019	Third annual re-assessment.	12/10/2023	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the

					medicinal product, concluded that marketing authorisation of MVABEA should be maintained.
II/0018/G	This was an application for a group of variations. Grouped application comprising three type II variations as follows: - Update of sections 4.8 and 5.1 of the SmPC in order to add vomiting to the list of adverse drug reactions (ADRs) in children with frequency common and to add immunogenicity data from study VAC52150EBL2004 (PREVAC), listed as a Study 3 in the agreed PIP. This was a randomised, double-blind, placebo-controlled, parallel-group Phase 2 study conducted at multiple sites in West Africa to investigate the immunogenicity and safety of 3 Ebola vaccine regimens versus placebo in adults (aged ≥18 years), adolescents (aged 12-17 years), and children (2 age strata: 5-11 years and 1-4 years) who never received a candidate Ebola vaccine (self-report) and had no history of Ebola virus disease (self-report). - Update of sections 4.2. 4.8 and 5.1 of the SmPC to add interim safety and immunogenicity data from study VAC52150EBL2005, a study conducted by the MAH in infants 4-11 months of age. - Update of section 5.1 of the SmPC to add final immunogenicity data from study VAC52150EBL2011, a study in which an Ad26.ZEBOV booster dose was evaluated in children 1 to 11 years of age (at the time of first vaccination in EBL3001). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce	20/07/2023	24/07/2024	SmPC and PL	For more information, please refer to the Summary of Product Characteristics.

	editorial changes and update the contact details of the local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
PSUSA/10857 /202209	Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN-Filo [recombinant])	14/04/2023	n/a		PRAC Recommendation - maintenance
IB/0016	B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product	08/12/2022	n/a		
PSUSA/10857 /202203	Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN-Filo [recombinant])	27/10/2022	n/a		PRAC Recommendation - maintenance
S/0015	Second annual re-assessment	13/10/2022	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of MVABEA should be maintained.
IB/0014	B.I.b.2.a - Change in test procedure for AS or	05/07/2022	n/a		

	starting material/reagent/intermediate - Minor changes to an approved test procedure				
IB/0012	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	10/05/2022	n/a		
PSUSA/10857 /202109	Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN-Filo [recombinant])	05/05/2022	n/a		PRAC Recommendation - maintenance
IB/0011	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	18/02/2022	n/a		
IB/0008	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	22/12/2021	n/a		
IAIN/0010/G	This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	21/12/2021	16/12/2022	Annex II and PL	
IB/0007	B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a	05/11/2021	n/a		

	new specification parameter to the specification with its corresponding test method				
PSUSA/10857 /202103	Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN-Filo [recombinant])	28/10/2021	n/a		PRAC Recommendation - maintenance
S/0006	First annual re-assessment.	14/10/2021	n/a		The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of MVABEA should be maintained.
N/0004	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	21/07/2021	16/12/2022	PL	
PSUSA/10857 /202009	Periodic Safety Update EU Single assessment - ebola vaccine (Ad26.ZEBOV-GP [recombinant], MVA-BN-Filo [recombinant])	06/05/2021	n/a		PRAC Recommendation - maintenance
IB/0003/G	This was an application for a group of variations. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	14/04/2021	n/a		
IB/0001	B.II.f.1.e - Stability of FP - Change to an approved stability protocol	24/11/2020	n/a		